1357-P: Real-World Glycemic Profiles and Insulin Use Patterns of 9,914 Pediatric and Adolescent Patients with Type 1 Diabetes Using the Omnipod® Insulin Management System with Cloud-Based Data Management

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1357-P
Author(s):  
JENNIFER E. LAYNE ◽  
YIBIN ZHENG ◽  
JIALUN HE ◽  
JAY JANTZ ◽  
ERIC BENJAMIN ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Data Management ◽  
Real World ◽  
Management System ◽  
Use Patterns ◽  
Adolescent Patients ◽  
Insulin Use

1043-P: Glycemic Profiles and Treatment Patterns: Real-World Data from 8,020 Adults with Type 1 Diabetes Using the Omnipod® Insulin Management System with Cloud-Based Data Management

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1043-P
Author(s):  
JENNIFER E. LAYNE ◽  
JIALUN HE ◽  
JAY JANTZ ◽  
YIBIN ZHENG ◽  
ERIC BENJAMIN ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Data Management ◽  
Real World ◽  
Management System ◽  
Treatment Patterns ◽  
Real World Data ◽  
World Data

scholarly journals Diabetes Data Management System to Improve Glycemic Control in People With Type 1 Diabetes: Prospective Cohort Study

2017 ◽  
Vol 5 (11) ◽  
pp. e170 ◽  
Author(s):  
Concetta Irace ◽  
Matthias Axel Schweitzer ◽  
Cesare Tripolino ◽  
Faustina Barbara Scavelli ◽  
Agostino Gnasso
Keyword(s):  
Type 1 Diabetes ◽  
Cohort Study ◽  
Glycemic Control ◽  
Data Management ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Management System ◽  
Data Management System

scholarly journals Diabetes Data Management System to Improve Glycemic Control in People With Type 1 Diabetes: Prospective Cohort Study (Preprint)

2017 ◽  
Author(s):  
Concetta Irace ◽  
Matthias Axel Schweitzer ◽  
Cesare Tripolino ◽  
Faustina Barbara Scavelli ◽  
Agostino Gnasso
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Glycemic Control ◽  
Data Management ◽  
Management System ◽  
Data Management System ◽  
Care Process ◽  
Self Monitoring ◽  
The Web

BACKGROUND Smartphone and Web technology can improve the health care process, especially in chronic diseases. OBJECTIVE The aim of this study was to investigate whether the use of blood glucose (BG) data management system, which enables connection to smartphones, the Web, the cloud, and downloading, can improve glycemic control in subjects with type 1 diabetes mellitus (T1DM). METHODS This study was a prospective, single-arm, cohort feasibility study with 6 months of duration. T1DM subjects enrolled had experience in self-monitoring blood glucose, but were download data naïve. Fasting BG and glycated hemoglobin (HbA1c) were collected at the enrollment and at follow-up. Subjects were divided into Downloader (DL) and No-downloader (NDL). RESULTS A total of 63 subjects were analyzed, of which 30 were classified as DL and 33 as NDL. At the end of the study, DL had significantly lower HbA1c, mean daily glucose, standard deviation, percentage of BG values above target, and pre- and postprandial (lunch and dinner) values compared with NDL (all P<.05). The percentage of BG values within treatment target was significantly higher in DL compared with NDL (47% [SD 9] vs 37% [SD 13]; P=.001). CONCLUSIONS The findings suggest that, in T1DM, downloading of BG from data management system, which enables connection to smartphones, the Web, and the cloud, might be a valuable contributor to improved glycemic control.

Glucose scan behaviour in people with type 1 diabetes using flash glucose monitoring in a real-world setting

2020 ◽  
Author(s):  
Daniel Hochfellner ◽  
Haris Ziko ◽  
Hesham Elsayed ◽  
Monika Cigler ◽  
Lisa Knoll ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Real World ◽  
Glucose Monitoring ◽  
Flash Glucose Monitoring ◽  
Real World Setting

1061-P: Effect of the Omnipod® Insulin Management System on Glycemic Control in Adults with Type 1 Diabetes Previously Treated with MDI or CSII

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1061-P
Author(s):  
SANJEEV N. MEHTA ◽  
DAVIDA F. KRUGER ◽  
BRUCE W. BODE ◽  
JENNIFER E. LAYNE ◽  
BONNIE DUMAIS ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Management System ◽  
Previously Treated

scholarly journals Perceptions of Adolescent Patients of the “Lived Experience” of Type 1 Diabetes

2017 ◽  
Vol 30 (1) ◽  
pp. 23-35 ◽  
Author(s):  
Kathryn M. King ◽  
Philip J. King ◽  
Rahul Nayar ◽  
Scott Wilkes
Keyword(s):  
Type 1 Diabetes ◽  
Lived Experience ◽  
Adolescent Patients

scholarly journals Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

2021 ◽  
pp. jim-2020-001633
Author(s):  
Florentino Carral San Laureano ◽  
Mariana Tomé Fernández-Ladreda ◽  
Ana Isabel Jiménez Millán ◽  
Concepción García Calzado ◽  
María del Carmen Ayala Ortega
Keyword(s):  
Type 1 Diabetes ◽  
Clinical Practice ◽  
Retrospective Study ◽  
Real World ◽  
Glycosylated Hemoglobin ◽  
Routine Clinical Practice ◽  
Insulin Analogs ◽  
Total P ◽  
Real Clinical Practice

There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL (IGlar-300) or degludec (IDeg) in real clinical practice. An observational, retrospective study was designed in 412 patients with T1D (males: 52%; median age 37.0±13.4 years, diabetes duration: 18.7±12.3 years) using IDeg and IGla-300 ≥6 months to compare DIDR between groups. Patients using IGla-300 (n=187) were more frequently males (59% vs 45.8%; p=0.004) and had lower glycosylated hemoglobin (HbA1c) (7.6±1.2 vs 8.1%±1.5%; p<0.001) than patients using IDeg (n=225). Total (0.77±0.36 unit/kg/day), basal (0.43±0.20 unit/kg/day) and prandial (0.33±0.23 unit/kg/day) DIDR were similar in IGla-300 and IDeg groups. Patients with HbA1c ≤7% (n=113) used significantly lower basal (p=0.045) and total (p=0.024) DIDR, but not prandial insulin (p=0.241), than patients with HbA1c between 7.1% and 8% and >8%. Patients using IGla-300 and IDeg used similar basal, prandial and total DIDR regardless of metabolic control subgroup. No difference in basal, prandial and total DIDR was observed between patients with T1D using IGla-300 or IDeg during at least 6 months in routine clinical practice.

Sign in / Sign up

Export Citation Format

Share Document